Vericel (VCEL) Stock Price, News & Analysis

Company Overview

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States.

Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

The company traces its roots to Aastrom Biosciences and adopted the Vericel name in 2014. Nick Colangelo serves as its chief executive officer.

Key Stats

• Today's Range: $57.76 to $59.75
• 50-Day Range: $37.87 to $59.03
• 52-Week Range: $28.95 to $59.75
• Volume: 809,201 shs
• Average Volume: 608,593 shs
• Market Capitalization: $3.03 billion
• P/E Ratio: 92.89
• Dividend Yield: N/A
• Price Target: $62.00
• Consensus Rating: Buy

Vericel Stock Analysis - MarketRank™

Vericel scored higher than 53% of companies evaluated by MarketBeat, and ranked 609th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Buy

Consensus Rating

Vericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Vericel is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Vericel has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 31.51%

Earnings Growth

Earnings for Vericel are expected to grow by 31.51% in the coming year, from $0.73 to $0.96 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vericel is 91.06, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vericel is 91.06, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.20.

Price to Book Value per Share Ratio

Vericel has a P/B Ratio of 7.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.34% of the float of Vericel has been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 9.83.

Change versus previous month

Short interest in Vericel has recently increased by 2.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vericel does not currently pay a dividend.

Dividend Growth

Vericel does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.70

News Sentiment

Vericel has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 47 news articles for Vericel this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Vericel to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,128,340.00 in company stock.

Percentage Held by Insiders

7.60% of the stock of Vericel is held by insiders.

Percentage Held by Institutions

Vericel has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VCEL
• CIK: 887359
• Web: www.vcel.com
• Phone: (617) 588-5555
• Fax: 617-588-5554
• Employees: 398
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vericel: $62.00
• High Price Target: $75.00
• Low Price Target: $46.00
• Potential Upside/Downside: +4.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.64
• Trailing P/E Ratio: 92.46
• Forward P/E Ratio: 61.81
• P/E Growth: N/A
• Net Income: $16.52 million
• Net Margins: 10.27%
• Pretax Margin: 10.54%
• Return on Equity: 9.09%
• Return on Assets: 6.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.13
• Quick Ratio: 4.82

Sales & Book Value

• Annual Sales: $276.26 million
• Price / Sales: 10.96
• Cash Flow: $0.56 per share
• Price / Cash Flow: 105.11
• Book Value: $7.53 per share
• Price / Book: 7.88

Miscellaneous

• Outstanding Shares: 51,030,000
• Free Float: 47,315,000
• Market Cap: $3.03 billion
• Optionable: Optionable
• Beta: 1.08